Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations-Reference-Cited by-同舟云学术

Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Published:2016-07 Issue:4 Volume:17 Page:245-252.e1
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Suh Koung Jin,Keam Bhumsuk,Kim Miso,Park Young Sik,Kim Tae Min,Jeon Yoon Kyung^ORCID,Kim Dong-Wan,Chung Doo Hyun,Kim Young Whan,Heo Dae Seog

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. EGFR testing in lung cancer is ready for prime time;Hirsch;Lancet Oncol,2009

2. Epidermal growth factor receptor inhibition in mutation-positive non–small-cell lung cancer: is afatinib better or simply newer?;Langer;J Clin Oncol,2013

3. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

4. Analysis of tumor specimens at the time of acquired resistance to EGFR TKI therapy in 155 patients with EGFR mutant lung cancers;Yu;Clin Cancer Res,2013

5. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation;Morinaga;Lung Cancer,2007

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low biofouling strategy for simultaneous determination of two proteins related to one tumor in human serum;Sensors and Actuators B: Chemical;2024-10

2. Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations;Neoplasia;2024-07

3. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update;Tumor Biology;2023-10-28

4. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study;Targeted Oncology;2023-08-23

5. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies;Tumor Biology;2023-05-23